Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Five Hedge Fund Moves in Healthcare Sector From This Week

The healthcare sector is usually very attractive to investors, since the companies involved in it have a great potential to grow. According to Morningstar data, the healthcare sector has a return of 39% year-to-date, being outrun by Consumer Cyclical and Technology sectors, which gained 40.6% and 54.61% respectively. Over this week, hedge funds have made several particularly interesting moves in companies from the healthcare sector. Since we have proven that tracking hedge fund activity can help retail investors to beat the market, we suggest you take a look at the list we have compiled below.

Arthur Cohen and Joseph Healey‘s Healthcor Management, has trimmed its stake in Allscripts Healthcare Solutions Inc (NASDAQ:MDRX), and now it owns 10 million shares, down by 1.0 million since the end of September. Healthcor holds an activist position in the company, which still amasses around 5.6% of its common stock.

Arthur B Cohen and Joseph Healey

Earlier this week, Julian Baker and Felix Baker‘s hedge fund Baker Bros. Advisors upped their stake in Seattle Genetics, Inc. (NASDAQ:SGEN) to a total of 20.9 million, from 20.5 million disclosed last week. Overall, Baker Bros. owns 17.1% of Seattle Genetics’ common stock.

Stephen DuBois‘ Camber Capital reported adding to its position in CONMED Corporation (NASDAQ:CNMD), raising the holding to 5.02% of stock. The stake amasses 1.4 million shares, and has been increased from 1.0 million shares owned by the fund at the end of September.

Orexigen Therapeutics, Inc. (NASDAQ:OREX) has been the target of Christopher Medlock James‘ Partner Fund Management. The fund revealed upping its position to 5.3 million shares, from 3.6 million held earlier. The passive stake amasses 5.2% of the company’s common stock.

The last on our list comes Jim Roumell‘s fund Roumell Asset Management, which in a letter sent to Transcept Pharmaceuticals Inc (NASDAQ:TSPT) disclosed that it salutes the company’s latest efforts. It also stated that Roumell will have a representative on Transcept’s Board. Roumell currently holds almost 2.18 million shares,  reducing the position from 2.25 million shares owned at the end of September via several transactions.

Disclosure: none

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!